Objective: The aim of this study was to identify if breast reconstruction is a surgical risk factor for axillary web syndrome (AWS) in breast cancer (BC) patients. Methods: The data of 207 patients who have been diagnosed with unilateral BC and who had mastectomy and lymph node dissection were retrospectively reviewed. Information of their clinical and pathological data, whether they had immediate -reconstruction and intraoperative radiotherapy, surgical methods, and postoperative complications during the 3 months after their surgery (AWS, lymphedema, seroma, and myofascial adhesion) were collected, and the incidence of AWS was compared between different surgical methods. -Results: The overall incidence of AWS was 48.8% in 207 patients. Of the 22 patients who received reconstruction, 19 developed AWS, yielding an incidence of 86%. Multivariate logistic regression modeling showed that patients who underwent reconstruction had a significantly higher incidence of AWS (odds ratio, 4.74), as did patients with postoperative complication of myofascial adhesion (odds ratio, 7.07). Conclusions: BC survivors after breast reconstruction are susceptible to AWS, and there is a significant association between myofascial adhesion and AWS. Our results can stimulate further investigation and provide an evidence base for the development of educational guidance for patients who plan to undergo breast reconstruction.

Axillary web syndrome (AWS), a condition that occurs after the interruption of the axillary lymphatic system, is characterized by “cording,” a visible and palpable web of taut tissue in the breast, underarm, medial arm, antecubital space, forearm, or abdominal wall, and is clinically associated with pain and limited shoulder range of motion [1-4] (Fig. 1).

Fig. 1.

A 45-year-old female with a palpable cording in the axilla extending down to the elbow after right BC surgery.

Fig. 1.

A 45-year-old female with a palpable cording in the axilla extending down to the elbow after right BC surgery.

Close modal

The incidence of AWS, which ranges from 28.1 to 48%, is frequently overlooked and not well defined [3, 4]. AWS generally develops within 1–5 weeks after surgery and can be resolved within 2–3 months [4, 5]. Since the cording is more prominent during shoulder abduction, its existence might hinder subsequent treatment by impairing the patients radiotherapy when their arm must be positioned overhead in abduction and external rotation [6-8].

The mechanism of AWS is not yet well established. Koehler [9] related the formation of cording to the healing process – inflammatory, proliferative (angiogenesis), and maturation phases that are in response to the disruption of the lymphatic system and the reconnections of lymph vessels (lymph angiogenesis). Eventually, the newly forming lymphatic vessels may become adhered to the underlying tissue and thus also become palpable to cording.

As advances in breast cancer (BC) treatments increase the patients’ survival rate, breast reconstruction becomes a choice for them to improve their body image and the fit of their clothing [10]. Many of the studies previously conducted on breast reconstruction have shown a favorable protective effect on the future development of lymphedema [10-13]. For example, the study by Card et al. [10] revealed that patients who undergo breast reconstruction have a lower incidence and a delay in the onset of BC-related lymphedema as compared with patients who undergo mastectomy alone.

Among the possible reasons for why reconstruction may be beneficial is that transferred vascularized tissue can bridge damaged lymphatics and reduce scarring following lymph node dissection [10, 11, 14-16]. In addition, vascularized tissue has the potential to restore lymphatic flow by promoting angiogenesis and lymphatic regeneration [10, 17].

However, it remains unclear if reconstruction is associated with a higher incidence of myofascial adhesion and/or cording formation. Thus, we have conducted this study to compare the various surgical methods/complications between the patients with and without AWS to identify the risk factors related to surgery for the incidence of AWS.

In adherence to the regulations for Breast Cancer Care Quality Assurance Measures by the Taiwan Ministry of Health and Welfare, we have established a clinical pathway to integrate physical evaluations and therapies in the continuous treatment and care protocol for cancer patients. Each patient with newly diagnosed BC and on surgical schedule will be referred to the rehabilitation department at time intervals of preoperative assessment and education, immediate postoperative assessment and therapies, 3–4 weeks postoperative assessment and therapies, and before and after chemotherapies and/or radiotherapies. The physical therapy assessment included measurement of shoulder range of motion, muscle strength, grasp power, existence of AWS, lymphedema, seroma, myofascial adhesion, and activities of daily life impairment. To assess AWS, the axilla was palpated, with the shoulder positioned in 90° of abduction. The patients with AWS were defined as those individuals who have palpable cording from the axilla to the upper limb when positioned with an affected shoulder abduction of 90° during any point of postoperative assessment within 3 months.

Through their medical records, we recruited patients who were diagnosed with unilateral BC and had surgical intervention from January 2016 to October 2017 (a partial mastectomy [PM] or total mastectomy [TM], including modified radical mastectomy) and lymph node dissection (ALND or SLNB) at the Ditmanson Medical Foundation of Chia-Yi Christian Hospital. Patients were excluded if they had undergone neoadjuvant chemotherapy or radiotherapy before surgery, were diagnosed with cancer recurrence or another cancer, had incomplete medical records, or were male. The clinical and pathological data were collected through chart reviews of medical, surgical, pathological, and physical therapy records including age, body weight, body length, BMI, maximum tumor size, removed soft tissue size, pathology, whether they had immediate reconstruction and intraoperative radiotherapy (IORT) or not, type of mastectomy (PM/TM), type of lymph node dissection (ALND/SLNB), number of lymph node dissections, operating time, and postoperative complications during the 3 months after surgery (AWS, lymphedema, seroma, and myofascial adhesion).

We expressed the continuous variables as the mean and standard deviation, and the qualitative variables as the percentage. The χ2 test and Student’s t test were used to compare the categorical and continuous data. The correlation between variables was examined using the Spearman and Pearson correlation coefficient when appropriate. Predictive effect of variables for AWS was performed by stepwise logistic regression. All statistical tests were conducted using SPSS for windows version 21.0 (SPSS; IBM Corporation, Somers, NY, USA) with a two-tailed significance level of 0.05.

We recruited 238 eligible patients diagnosed with unilateral BC and had pre-and post-operative assessments at Ditmanson Medical Foundation Chia-Yi Christian Hospital. After excluding 11 patients who had received neoadjuvant chemotherapy or radiotherapy before surgery, 11 patients who had another cancer or recurring cancer, 8 patients who had incomplete medical records, and 1 male patient, we collected the complete data for 207 patients. Of the 207 participants analyzed, 101 were in the AWS group and 106 were in the control group, yielding an incidence of 48.8%.

Out of the 207 patients, 111 (53.6%) underwent TM and 96 (46.4%) underwent PM, 87 of them (42.0%) underwent ALND and 120 (58.0%) underwent SLND, and 22 (10.6%) underwent reconstruction while 35 (16.9%) underwent IORT. Among the 22 patients with breast reconstruction, there were 19 autologous tissues (16 deep inferior epigastric perforator and 3 transverse rectus abdominis myocutaneous flaps) and 3 implants. The average age of the patients was 52.2 years, while the average BMI at surgery was 23.6 (Table 1).

Table 1.

Patient characteristics

Patient characteristics
Patient characteristics

Out of the 22 patients who received reconstruction, 19 developed AWS, yielding an incidence rate of 86%. Univariate logistic regression modeling showed the odds ratio of AWS being associated with reconstruction as 7.96 (95% confidence interval [CI], 2.28–27.82; p = 0.001) (Table 2). Patients with postoperative complication of scar tissue adhesion had a greater than six-fold higher incidence of AWS as compared with patients without (odds ratio, 6.69; 95% CI, 2.21–20.28; p = 0.001) (Table 2). Other risk factors of AWS included body weight (BW), BMI, and operation time (Table 2).

Table 2.

Univariate logistic regression model of the incidence of AWS (n = 207)

Univariate logistic regression model of the incidence of AWS (n = 207)
Univariate logistic regression model of the incidence of AWS (n = 207)

To prevent bias from including high correlation variables (r ≥ 0.7) [18] in multivariate logistic regression model, we analyzed the correlation of variables related to AWS. BMI is defined as BW divided by the square of body length (BL), and as a result, it had a high correlation with BW (r = –0.997) and BL (r = 0.989). The type of mastectomy (PM or TM) was highly correlated with removed soft tissue size (r = –0.797). Similarly, the type of lymph node dissection (ALND or SLNB) was highly correlated with the number of lymph node dissections (r = –0.737). Finally, reconstruction surgery costs more time than mastectomy alone, hence why reconstruction was highly correlated with operation time (r = –0.711). Therefore, we excluded BW, BL, removed soft tissue size, number of lymph node dissections, and operating time to identify the risk factors related to surgery for the incidence of AWS. The remaining variables including age, BMI, tumor size, date of assessment, type of mastectomy (PM/TM), type of lymph node dissection (ALND/SLND), IORT, scar tissue adhesion, and seroma were all independent variables for AWS. Multivariate logistic regression modeling showed that patients who underwent reconstruction had a significantly higher incidence of AWS (odds ratio, 4.74), and those with postoperative complication of scar tissue adhesion also had a significantly higher incidence of AWS (odds ratio, 7.07) (Table 3). Breast reconstruction and scar tissue adhesion were significantly associated with AWS.

Table 3.

Multivariate logistic regression model of the incidence of AWS (n = 207)

Multivariate logistic regression model of the incidence of AWS (n = 207)
Multivariate logistic regression model of the incidence of AWS (n = 207)

The major finding of this study is that BC survivors after breast reconstruction were susceptible to AWS as the incidence was up to 86% (19/22), and there was also evidence of a significantly higher risk of AWS (odds ratio, 4.74) when compared with those who underwent mastectomy alone. Because there were scanty studies examining the correlation between AWS and breast reconstruction, we could only find one related article that investigated the clinical and ultrasonographic characteristics of AWS in 36 patients with surgical BC at time intervals of 2 weeks, 4 weeks, and 3 months postoperatively. Their data revealed a 60% (3/5) incidence of AWS in the patients who underwent breast reconstruction [9], but the case numbers of breast reconstruction was too small to make a comparison.

The mechanism behind the higher incidence of AWS in BC survivors after breast reconstruction remains unclear. Most of the previous research regarding damaged upper-limb lymphatic drainage focused on the correlation between the future development of lymphedema and breast reconstruction, and the procedure of reconstructing vessels was hypothesized to be able to help reconnect lymphatic flow and possibly promote angiogenesis and lymphatic regeneration [9-17]. On the other hand, the formation of cording might be a result of the reconnection of damaged lymph vessels (lymph angiogenesis). We speculate that breast reconstruction may help drain the blockage of lymphatics and thus prevent lymphedema, whereas the newly forming lymphatic vessels may cause the formation of cording in the healing process. This hypothesis warrants further investigation.

We also found a significant correlation between myofascial adhesion and AWS (odds ratio, 7.07). In addition, myofascial adhesion and reconstruction were independent risk factors for AWS because of a low interaction effect (r = –0.089). We speculate that myofascial adhesion caused by scar fibrosis may lead to obstruction of lymphatic drainage, thus making it subject to the formation of cording.

The overall incidence rate of AWS was 48.8% in our study. In the review article by Yeung et al. [8], the incidence of AWS ranged from 0.6% to 85.4%, depending on the timing and methods of the assessment and was frequently overlooked. We diagnosed patients with AWS by expert physical therapists during the routine physical assessment, and the incidence rate of 48.8% was similar to the incidence rate of 47.2% in the study conducted by Koehler [9] who used similar diagnostic methods. Physiotherapy has been reported to improve shoulder range of motion, to reduce pain, and to shorten cording resolution time [8, 19, 20]. Given the high incidence rate of AWS among BC survivors after breast reconstruction, we advocate for preoperative education about the possibility of developing signs and symptoms of AWS as well as the integration of postoperative assessment and management into the BC treatment protocol. Furthermore, since cording restricts the range of motion of shoulder abduction [4], medical professionals should plan subsequent radiotherapy with the impact of AWS in mind.

To our knowledge, this is the first study to investigate the correlation between AWS and breast reconstruction. The results from this study could serve as an educational guidance for patients who plan to undergo breast reconstruction and stimulate further investigation.

BC survivors after breast reconstruction are susceptible to AWS, and there is a significant correlation between myofascial adhesion and AWS. This is the first study to investigate the correlation between AWS and breast reconstruction. Our results provide a significant evidence base for developing educational guidance for those patients who plan to undergo breast reconstruction and stimulate further investigation.

We thank Guo How-Ran, Ph.D., at the Department of Occupational and Environmental Health, National Cheng Kung University, for providing suggestions regarding statistics and a critical review of the proposal for this study.

The local ethical committee of Chia-Yi Christian Hospital approved this study in accordance with the Declaration of Helsinki. The study was performed under the Nos. 106008 and 2018004 from the local Ethics Committee of Chia-Yi Christian Hospital.

The authors declare that they have no competing interests. We declare that no party with a direct interest in the results of the research supporting this article has or will confer benefits to us or any organization we are associated with.

We thank Chia-Yi Christian Hospital in Taiwan for the financial support (grant No. R106-18).

H.-C.H. conceived of the study, participated in its design and coordination, and drafted the manuscript. C.-H.W. participated in the design of the study and performed the statistical analysis. H.-H.L. and L.-Y.Y. were the main contributors to the data acquisition. C.-L.F. and C.-S.Y. participated in the interpretation of the data and helped draft the manuscript. All authors read and approved the final manuscript.

1.
Ferreira Rezende
L
,
Laier Franco
R
,
Costa Gurgel
MS
.
Axillary web syndrome: practical implications
.
Breast J
.
2005
Nov-Dec
;
11
(
6
):
531
.
[PubMed]
1075-122X
2.
Leduc
O
,
Sichere
M
,
Moreau
A
,
Rigolet
J
,
Tinlot
A
,
Darc
S
, et al
Axillary web syndrome: nature and localization
.
Lymphology
.
2009
Dec
;
42
(
4
):
176
81
.
[PubMed]
0024-7766
3.
Bergmann
A
,
Mendes
VV
,
de Almeida Dias
R
,
do Amaral E Silva
B
,
da Costa Leite Ferreira
MG
,
Fabro
EA
.
Incidence and risk factors for axillary web syndrome after breast cancer surgery
.
Breast Cancer Res Treat
.
2012
Feb
;
131
(
3
):
987
92
.
[PubMed]
0167-6806
4.
Huang
HC
,
Liu
HH
,
Yin
LY
,
Yeh
CH
,
Tu
CW
,
Yang
CS
.
The upper-limb volumetric changes in breast cancer survivors with axillary web syndrome
.
Eur J Cancer Care (Engl)
.
2017
Mar
;
26
(
2
):
e12637
.
[PubMed]
0961-5423
5.
Aydogan
F
,
Belli
AK
,
Bağhaki
S
,
Karabulut
K
,
Tahan
G
,
Uras
C
.
Axillary web syndrome after sentinel node biopsy
.
Breast Care (Basel)
.
2008
;
3
(
4
):
277
8
.
[PubMed]
1661-3791
6.
Josenhans
E
.
Physiotherapeutic treatment for axillary cord formation following breast cancer surgery. Pt_
.
Z Physiother
.
2007
;
59
:
868
78
.1614-0397
7.
Lattanzi
JB
,
Zimmerman
A
,
Marshall
LM
.
Case report of axillary web syndrome
.
Rehabil Oncol
.
2012
;
30
(
1
):
18
21
.
8.
Yeung
WM
,
McPhail
SM
,
Kuys
SS
.
A systematic review of axillary web syndrome (AWS)
.
J Cancer Surviv
.
2015
Dec
;
9
(
4
):
576
98
.
[PubMed]
1932-2259
9.
Koehler
L
.
Axillary web syndrome ongoing medical evaluation
[Dissertation]: University of Minnesota
2013
.
10.
Card
A
,
Crosby
MA
,
Liu
J
,
Lindstrom
WA
,
Lucci
A
,
Chang
DW
.
Reduced incidence of breast cancer-related lymphedema following mastectomy and breast reconstruction versus mastectomy alone
.
Plast Reconstr Surg
.
2012
Dec
;
130
(
6
):
1169
78
.
[PubMed]
0032-1052
11.
Chang
DW
,
Kim
S
.
Breast reconstruction and lymphedema
.
Plast Reconstr Surg
.
2010
Jan
;
125
(
1
):
19
23
.
[PubMed]
0032-1052
12.
Menezes
MM
,
Bello
MA
,
Millen
E
,
Lucas
FA
,
Carvalho
FN
,
Andrade
MF
, et al
Breast reconstruction and risk of lymphedema after mastectomy: A prospective cohort study with 10 years of follow-up
.
J Plast Reconstr Aesthet Surg
.
2016
Sep
;
69
(
9
):
1218
26
.
[PubMed]
1748-6815
13.
Miller
CL
,
Colwell
AS
,
Horick
N
,
Skolny
MN
,
Jammallo
LS
,
O’Toole
JA
, et al
Immediate implant reconstruction is associated with a reduced risk of lymphedema compared to mastectomy alone: a prospective cohort study
.
Ann Surg
.
2016
Feb
;
263
(
2
):
399
405
.
[PubMed]
0003-4932
14.
Chitale
VR
.
Role of tensor fascia lata musculocutaneous flap in lymphedema of the lower extremity and external genitalia
.
Ann Plast Surg
.
1989
Oct
;
23
(
4
):
297
304
.
[PubMed]
0148-7043
15.
Withey
S
,
Pracy
P
,
Wood
S
,
Rhys-Evans
P
.
The use of a lymphatic bridge in the management of head and neck lymphoedema
.
Br J Plast Surg
.
2001
Dec
;
54
(
8
):
716
9
.
[PubMed]
0007-1226
16.
Classen
DA
,
Irvine
L
.
Free muscle flap transfer as a lymphatic bridge for upper extremity lymphedema
.
J Reconstr Microsurg
.
2005
Feb
;
21
(
2
):
93
9
.
[PubMed]
0743-684X
17.
Slavin
SA
,
Van den Abbeele
AD
,
Losken
A
,
Swartz
MA
,
Jain
RK
.
Return of lymphatic function after flap transfer for acute lymphedema
.
Ann Surg
.
1999
Mar
;
229
(
3
):
421
7
.
[PubMed]
0003-4932
18.
Hazra
A
,
Gogtay
N
.
Biostatistics Series Module 6: Correlation and Linear Regression
.
Indian J Dermatol
.
2016
Nov-Dec
;
61
(
6
):
593
601
.
[PubMed]
0019-5154
19.
Fourie
WJ
,
Robb
KA
.
Physiotherapy management of axillary web syndrome following breast cancer treatment: discussing the use of soft tissue techniques
.
Physiotherapy
.
2009
Dec
;
95
(
4
):
314
20
.
[PubMed]
0031-9406
20.
Wyrick
SL
,
Waltke
LJ
,
Ng
AV
.
Physical therapy may promote resolution of lymphatic coding in breast cancer survivors
.
Rehabil Oncol
.
2006
;
24
(
1
):
29
34
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.